EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nicotine and cotinine enhance SARS-CoV-2 entry through distinct but complementary mechanisms in human respiratory epithelial cells

Jiheng Xu, Huei-Wei Chan, Rui Yang, Xue-Ru Wu, Priyangi Malaviarachchi, He Wang, Xuming Zhang iD, Moon-Shong Tang iD

Journal of Virology · 18.08.2026 · 100 (8)

DOI: 10.1128/jvi.00971-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 18.08.2026. Verfasst von Jiheng Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Environmental Medicine, Department of Medicine, Pathology, and Urology, New York University Grossman School of Medicine, New York, New Yo…. Hauptthemen laut MEDLINE: Nicotine, Virus Internalization, SARS-CoV-2, Epithelial Cells. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, UAMS | College of Medicine, University of Arkansas for Medical Sciences (College of Medicine).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previous epidemiological studies have shown that E-cigarette and tobacco users are more likely to develop COVID-19 symptoms than non-users. To investigate the underlying mechanisms, we examined the effects of nicotine, the major component of tobacco and E-cigarette, and its major metabolite, cotinine, on the susceptibility of human respiratory epithelial cells to SARS-CoV-2 infection. We found that pre-treatment with nicotine and cotinine significantly and additively enhanced viral infection. While nicotine increased the expression of the viral receptor ACE2 and the serine protease TMPRSS2, cotinine upregulated cysteine protease cathepsin B and promoted viral spike protein cleavage. These findings suggest that nicotine and cotinine enhance SARS-CoV-2 infection at the cell entry stage through distinct mechanisms. Using a SARS-CoV-2 pseudovirus system, we further investigated the effects and mechanisms of nicotine and cotinine on viral entry. We found that both compounds enhanced pseudovirus infection, but with different time courses. Nicotine’s effect correlated with the upregulation of ACE2 and TMPRSS2, whereas cotinine’s effect corresponded with increased cathepsin B and viral spike protein cleavage. The cathepsin B inhibitor E64d completely abolished cotinine-enhanced viral spike protein cleavage and viral entry. In contrast, ACE2 and TMPRSS2 inhibitors (chloromethylketone and camostat) had limited effects on viral spike protein cleavage and only partially reduced the viral entry enhancement induced by nicotine and cotinine. These results indicate that nicotine promotes virus-receptor binding and cell entry, while cotinine facilitates viral entry through cathepsin B-mediated spike protein cleavage. IMPORTANCE This study highlights the potential risks of tobacco and E-cigarette use in increasing susceptibility to COVID-19. We show that the major neurostimulant in tobacco and E-cigarette, nicotine, and its metabolite, cotinine, additively enhance SARS-CoV-2 infection in human respiratory epithelial cells by promoting viral entry. Specifically, nicotine and cotinine upregulate the expression of distinct, yet complementary sets of key cellular proteins required for viral entry. These findings suggest that both tobacco smoking and E-cigarette vaping may exacerbate COVID-19 infection rates and severity and provide new insights into how nicotine and cotinine contribute to viral susceptibility. This research underscores the need for public health measures to address the heightened risk posed by tobacco smoking and E-cigarette vaping to encounter the SARS-CoV-2 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NicotineVirus InternalizationSARS-CoV-2Epithelial CellsCotinineCOVID-19Respiratory MucosaHumansSpike Glycoprotein, CoronavirusCathepsin BAngiotensin-Converting Enzyme 2Serine EndopeptidasesCell Line

Stichwörter der Autor:innen

SARS-CoV-2cotininenicotineviral-cell-entryviral-spike-protein cleavage

Substanzen

NicotineSpike Glycoprotein, CoronavirusCathepsin BAngiotensin-Converting Enzyme 2TMPRSS2 protein, humanSerine EndopeptidasesCotininespike protein, SARS-CoV-2ACE2 protein, humanCTSB protein, human

Autor:innen und Institutionen

  • Division of Environmental Medicine, Department of Medicine, Pathology, and Urology, New York University Grossman School of Medicine, New York, New York, USA.
  • Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.

ORCID-Profile: Xuming Zhang, Moon-Shong Tang

Förderung

  • NCI NIH HHS
  • NIH HHS
  • UAMS | College of Medicine, University of Arkansas for Medical Sciences (College of Medicine)
  • National Institutes of Health

Zitieren

APA

Xu, J., Chan, H., Yang, R., Wu, X. R., Malaviarachchi, P., Wang, H., Zhang, X., & Tang, M. (2026). Nicotine and cotinine enhance SARS-CoV-2 entry through distinct but complementary mechanisms in human respiratory epithelial cells. Journal of Virology, 100(8). https://doi.org/10.1128/jvi.00971-26

Vancouver

Xu J, Chan H, Yang R, Wu XR, Malaviarachchi P, Wang H, et al. Nicotine and cotinine enhance SARS-CoV-2 entry through distinct but complementary mechanisms in human respiratory epithelial cells. Journal of Virology. 2026;100(8). doi:10.1128/jvi.00971-26

BibTeX
@article{Xu2026,
  author = {Xu, Jiheng and Chan, Huei-Wei and Yang, Rui and Wu, Xue-Ru and Malaviarachchi, Priyangi and Wang, He and Zhang, Xuming and Tang, Moon-Shong},
  title = {Nicotine and cotinine enhance SARS-CoV-2 entry through distinct but complementary mechanisms in human respiratory epithelial cells},
  journal = {Journal of Virology},
  year = {2026},
  volume = {100},
  number = {8},
  doi = {10.1128/jvi.00971-26}
}
Kostenlos starten →